Organovo sees cash runway through the end of FY26

Written by Emily J. Thompson, Senior Investment Analyst

ONVO%

Updated: Mar 27 2025

0mins

Business Update: Organovo Holdings has completed the sale of its FXR Program to Lilly, receiving upfront payments and anticipating future milestone payments, which positions the company for further success in IBD opportunities while reducing expenditures related to the FXR program.
Financial Outlook: The company plans to establish an operating cadence that optimizes existing capital until FY2026, with full-year financials expected to be reported between June 6-10, 2025, leveraging its 3D human cellular models to evaluate therapeutic opportunities for Crohn's disease and ulcerative colitis.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Organovo sees cash runway through the end of FY26

About the author

Top News

Oil Firms Cautious on Venezuela Investment Push

GM Reports $7.1 Billion Charge Amid EV Shift

Stock Market Wraps 2025 with Double-Digit Gains

Novo Nordisk's Weight-Loss Pill Approval: Key Impacts

Related Articles

Vistagen Therapeutics Faces Class Action Lawsuit with Deadline for Lead Plaintiff by March 16, 2026

Monero (XMR) Surges 44% in Five Days, Yet Investment Risks Persist

Sigh Up to Get Intellectia Insights

How did the company's recent strategic decisions impact its latest financial performance?

Can you explain the factors behind the recent changes in the company's stock price?

What are the expected impacts of current market trends on the company's future growth?

Based on the latest earnings report, what are the company's forecasted revenues for the next quarter?

How does the company's performance compare to its main competitors in the same sector?

People Also Watch